JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Price:
2.47
HKD
4.22%
Market Closed
Market Cap:
HK$1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
CN |
Income Statement
Earnings Waterfall
JW (Cayman) Therapeutics Co Ltd
JW (Cayman) Therapeutics Co Ltd
Income Statement
JW (Cayman) Therapeutics Co Ltd
JW (Cayman) Therapeutics Co Ltd
Currency: CNY
| Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Interest Expense |
1
|
1
|
3
|
5
|
7
|
10
|
12
|
13
|
12
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
31
N/A
|
97
+214%
|
146
+51%
|
167
+15%
|
174
+4%
|
173
-1%
|
158
-9%
|
178
+12%
|
284
+60%
|
|
| Gross Profit | ||||||||||||
| Cost of Revenue |
0
|
0
|
(22)
|
(65)
|
(87)
|
(87)
|
(86)
|
(86)
|
(81)
|
(79)
|
(111)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
9
N/A
|
32
+256%
|
59
+83%
|
80
+37%
|
88
+10%
|
87
-1%
|
77
-11%
|
99
+28%
|
173
+75%
|
|
| Operating Income | ||||||||||||
| Operating Expenses |
(476)
|
(651)
|
(783)
|
(809)
|
(756)
|
(745)
|
(658)
|
(771)
|
(536)
|
(563)
|
(379)
|
|
| Selling, General & Administrative |
(242)
|
(311)
|
(368)
|
(391)
|
(362)
|
(312)
|
(246)
|
(238)
|
(260)
|
(216)
|
(233)
|
|
| Research & Development |
(214)
|
(314)
|
(391)
|
(390)
|
(367)
|
(394)
|
(362)
|
(305)
|
(283)
|
(224)
|
(188)
|
|
| Depreciation & Amortization |
(14)
|
(18)
|
(27)
|
(40)
|
(49)
|
(54)
|
(59)
|
(55)
|
(64)
|
0
|
0
|
|
| Other Operating Expenses |
(6)
|
(8)
|
4
|
12
|
23
|
16
|
8
|
(173)
|
71
|
(124)
|
42
|
|
| Operating Income |
(476)
N/A
|
(651)
-37%
|
(774)
-19%
|
(777)
0%
|
(697)
+10%
|
(665)
+5%
|
(570)
+14%
|
(684)
-20%
|
(459)
+33%
|
(465)
-1%
|
(206)
+56%
|
|
| Pre-Tax Income | ||||||||||||
| Interest Income Expense |
(3)
|
63
|
72
|
(74)
|
(149)
|
(133)
|
(16)
|
56
|
1
|
(0)
|
10
|
|
| Non-Reccuring Items |
6
|
0
|
0
|
0
|
(0)
|
0
|
(182)
|
0
|
(132)
|
(153)
|
(356)
|
|
| Total Other Income |
(1 191)
|
(706)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(1 664)
N/A
|
(1 294)
+22%
|
(702)
+46%
|
(851)
-21%
|
(846)
+1%
|
(797)
+6%
|
(768)
+4%
|
(628)
+18%
|
(591)
+6%
|
(618)
-5%
|
(552)
+11%
|
|
| Net Income | ||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
|
| Income from Continuing Operations |
(1 664)
|
(1 294)
|
(702)
|
(851)
|
(846)
|
(797)
|
(768)
|
(628)
|
(591)
|
(618)
|
(555)
|
|
| Net Income (Common) |
(1 664)
N/A
|
(1 294)
+22%
|
(702)
+46%
|
(851)
-21%
|
(846)
+1%
|
(797)
+6%
|
(768)
+4%
|
(628)
+18%
|
(591)
+6%
|
(618)
-5%
|
(555)
+10%
|
|
| EPS (Diluted) |
-12.61
N/A
|
-3.27
+74%
|
-1.76
+46%
|
-2.09
-19%
|
-2.06
+1%
|
-1.94
+6%
|
-1.87
+4%
|
-1.52
+19%
|
-1.43
+6%
|
-1.49
-4%
|
-1.34
+10%
|
|
Switch to:
Switch to:
See Also
Discover More
